0000000000319933

AUTHOR

P.a. Sáiz

showing 3 related works from this author

Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum

2020

The EUGEI project was supported by the European Community’s Seventh Framework Program under grant agreement no. HEALTH-F2-2009-241909 (Project EU-GEI). Dr O’Donovan is supported by MRC programme grant (G08005009) and an MRC Centre grant (MR/ L010305/1). Dr Rutten was funded by a VIDI award number 91718336 from the Netherlands Scientific Organisation. Drs Guloksuz and van Os are supported by the Ophelia research project, ZonMw grant number: 636340001. Dr Arango was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024); CIBERSAM; Madrid Regional Government (B2017/BMD-3740, AGES-CM-2); Fundación Familia Alonso and Fundac…

AdultMaleExposomePsychosisMultifactorial InheritanceEpidemiologyBIRTHSchizotypystructured interviewGENE-ENVIRONMENTPopulationschizotypypopulationEnvironment03 medical and health sciences0302 clinical medicineMedicineHumansSpectrum disorderGenetic Predisposition to DiseasegeneticspsychosiseducationMETAANALYSISvalidationRISKeducation.field_of_studychildhood traumareliabilitybusiness.industryPublic Health Environmental and Occupational HealthAbsolute risk reductionassociationRegression analysisGenomicsmedicine.disease3. Good health030227 psychiatryPsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniaFemaleGene-Environment InteractionSchizophrenic PsychologyOriginal Articlebusiness030217 neurology & neurosurgeryClinical psychologyEpidemiology and Psychiatric Sciences
researchProduct

Treatments for Opioid Dependence and Methadone

2016

Abstract This chapter is focused on opioid dependence treatment and is framed in a holistic perspective. Specifically, there are three main approaches to pharmacological treatment of opioid dependence: opioid detoxification, agonist maintenance, and antagonist maintenance. There is a great amount of evidence supporting the efficacy of methadone and buprenorphine or the combination of buprenorphine–naloxone for the treatment of opioid withdrawal and their clinical utility as pharmacotherapy in long-term maintenance programs. Secondary or adjunctive medications such as heroin, naltrexone, and alpha-2-adrenergics are also reviewed. The need for further research and to overcome nonscientificall…

medicine.medical_specialtybusiness.industry(+)-NaloxoneNaltrexoneHeroinPharmacotherapyOpioidDetoxificationMedicinebusinessIntensive care medicineBuprenorphinemedicine.drugMethadone
researchProduct

Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study

2022

The EUGEI project was supported by the European Community’s Seventh Framework Program under grant agreement No. HEALTH-F2- 2009-241909 (Project EU-GEI). Dr. Arango was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16-PE07CP1, PI16/02012, PI19/024); CIBERSAM (...)

AdultMalePsychosisGENETIC RISKInterviews as Topic03 medical and health sciencesSTRUCTURED INTERVIEW0302 clinical medicinePolygenic risk scoreRisk FactorsSocial cognitionIMPUTATIONmedicineHumansPOLYGENIC RISKEmotion recognitionAssociation (psychology)Biological PsychiatryEmotionPharmacologyIntermediate phenotypebusiness.industrySiblingsUNAFFECTED SIBLINGSRegression analysisASSOCIATIONGenomicsmedicine.diseaseSocial cognition030227 psychiatrySchizotypal traitsINDIVIDUALSPolygenic risk scoresPhenotypePsychotic DisordersSchizophreniaRELIABILITYStructured interviewSchizophreniaFemalebusinessFacial Recognition030217 neurology & neurosurgeryClinical psychologyProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct